IVIG is an intravenous formulation of immunoglobulin therapy. This is the use of a mixture of antibodies to treat a number of health conditions. These conditions include primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, Guillan Barré syndrome and in certain infections.
Common side effects include muscle pain and allergic reactions. Other more severe side effects include kidney problems, anaphylaxis, bloot clots and red blood cell breakdown.
Human immunoglobulin is made from blood plasma which contains antibodies against a large number of viruses and common infections.
Immunoglobulin therapy is used in a number of conditions in which antibody production is abolished and in disorders in which the antibodies lack quality and are unable to respond to antigens as they normally should. In these conditions immunoglobulin infusions give passive resistance to infection by increasing the quantity and quality of the immunoglobulins of the recipient.
One study of PANDAS patients showed efficacy of immunomodulatory therapy with intravenous immunoglobulins to symptoms. Kalra and Swedo, experts on PANDAS, state that the use of IVIG should be reserved for children with particularly severe symptoms and a clear cut PANDAS presentation because IVIG carries substantial risk of adverse events.
For patients with persistent symptoms due to Lyme disease there is no data that shows its efficacy.